当前位置: 首页 >> 检索结果
共有 18989 条符合本次的查询结果, 用时 4.1812617 秒

161. Detection of large flat colorectal lesions by artificial intelligence: a persistent weakness and blind spot.

作者: Douglas K Rex.;John J Guardiola.;Daniel von Renteln.;Yuichi Mori.;Prateek Sharma.;Cesare Hassan.
来源: Gut. 2025年74卷6期881-883页

162. Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study.

作者: Ze-Rong Cai.;Yong-Qiang Zheng.;Yan Hu.;Meng-Yao Ma.;Yi-Jin Wu.;Jia Liu.;Lu-Ping Yang.;Jia-Bo Zheng.;Tian Tian.;Pei-Shan Hu.;Ze-Xian Liu.;Lin Zhang.;Rui-Hua Xu.;Huai-Qiang Ju.
来源: Gut. 2025年74卷6期884-893页
Gastric cancer (GC) remains a prevalent and preventable disease, yet accurate early diagnostic methods are lacking. Exosome non-coding RNAs (ncRNAs), a type of liquid biopsy, have emerged as promising diagnostic biomarkers for various tumours. This study aimed to identify a serum exosome ncRNA feature for enhancing GC diagnosis.

163. Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus.

作者: Jing Tong Tan.;Xianhua Mao.;Ho-Ming Cheng.;Wai-Kay Seto.;Wai-K Leung.;Ka-Shing Cheung.
来源: Gut. 2025年74卷4期603-612页
Patients with type 2 diabetes mellitus (T2DM) have higher pancreatic cancer (PC) risk. While aspirin has chemopreventive effects on digestive cancers, its effect on PC among patients with T2DM is unclear.

164. Accuracy of histopathology evaluation in diminutive colonic polyps diagnosed as neoplastic by computer-aided characterisation.

作者: Roupen Djinbachian.;Heiko Pohl.;Douglas K Rex.;Alan Barkun.;Cesare Hassan.;Geneviève Soucy.;Bich N Nguyen.;Daniel von Renteln.
来源: Gut. 2025年74卷5期703-705页

165. Frequency of de novo PRSS1 pathogenic variants in a French cohort of idiopathic pancreatitis.

作者: Emmanuelle Masson.;Anne-Laure Vedie.;Frédérique Maire.;Tiphaine Godet.;Louis Buscail.;Vinciane Rebours.;Claude Férec.;Jian-Min Chen.
来源: Gut. 2025年74卷6期1028-1030页

166. Trends and cross-country inequality in the incidence of GI cancers among the working-age population from 1990 to 2021: a Global Burden of Disease 2021 analysis.

作者: Yiming Song.;Xiaoyi Wang.;Yufeng Shen.;Liping Chen.;Liuyi Yang.;Ruilan Wang.;Junyu Lu.;Zhifang Gao.;Xiaolu Lin.;Yan Song.;Qingwei Zhang.;Xiaobo Li.
来源: Gut. 2025年74卷6期948-959页
GI cancers pose an increasing global health burden, with their impact on the working-age population (WAP) aged 15-64 years remaining largely unexplored despite the crucial role of this group in societal and economic well-being.

167. Colonic motility investigation by modern techniques: time to 'reclaim' the value of physiology?

作者: Gabrio Bassotti.
来源: Gut. 2025年74卷6期1026-1027页

168. SPHINX, a Guardian of Wisdom.

作者: Anke Onnekink.;Roy L J van Wanrooij.;Jeanin E Van Hooft.
来源: Gut. 2025年74卷6期1027-1028页

169. Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma.

作者: Ekaterina Zhuravleva.;Monika Lewinska.;Colm J O'Rourke.;Antonio Pea.;Asif Rashid.;Ann W Hsing.;Andrzej Taranta.;David Chang.;Yu-Tang Gao.;Jill Koshiol.;Rui Caetano Oliveira.;Jesper B Andersen.
来源: Gut. 2025年74卷5期804-814页
Ampullary carcinoma (AMPAC) taxonomy is based on morphology and immunohistochemistry. This classification lacks prognostic reliability and unique genetic associations. We applied an approach of integrative genomics characterising patients with AMPAC exploring molecular subtypes that may guide personalised treatments.

171. Are histamine-2 receptor antagonists a reasonable comparator: comparing apples and apples?

作者: Lizhi Hu.;Yu Peng.
来源: Gut. 2025年74卷6期1024-1025页

172. Dysbiosis exists in unaffected relatives of inflammatory bowel disease (IBD): emphasising the critical phases in the developmental trajectory of gut microbiota.

作者: Jingwan Zhang.
来源: Gut. 2025年74卷7期1035-1037页

173. Faecalibacterium prausnitzii: one species with multiple potential implications in cancer research.

作者: Rodrigo Formiga.;Harry Sokol.
来源: Gut. 2025年74卷7期1038-1039页

174. Early detection of colorectal cancer using aberrant circulating cell-free mitochondrial DNA fragmentomics.

作者: Siyuan Wang.;Fan Peng.;Miao Dang.;Huanmin Jiao.;Huanqin Zhang.;Kaixiang Zhou.;Wenjie Guo.;Zhiyun Gong.;Lin Guo.;Renquan Lu.;Deliang Li.;Bingrong Liu.;Xu Guo.;Jinliang Xing.;Yang Liu.
来源: Gut. 2025年74卷6期961-970页
Early detection of colorectal cancer (CRC) is crucial for improving the survival rates of patients.

175. Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.

作者: Yating Zhang.;Mingxu Xie.;Jun Wen.;Cong Liang.;Qian Song.;Weixin Liu.;Yali Liu.;Yang Song.;Harry Cheuk Hay Lau.;Alvin Ho-Kwan Cheung.;Kwan Man.;Jun Yu.;Xiang Zhang.
来源: Gut. 2025年74卷4期639-651页
Transmembrane 6 superfamily member 2 (TM6SF2) has a protective role against metabolic dysfunction-associated steatotic liver disease (MASLD).

176. Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study.

作者: Jeremy Adler.;Samir Gadepalli.;Moshiur Rahman.;Sandra Kim.
来源: Gut. 2025年74卷4期539-546页
One in three children with Crohn's disease develop perianal fistula complications (PFCs), among the most disturbing and difficult-to-treat disease-related complications. Retrospective evidence suggests PFCs may be preventable.

177. Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies.

作者: Pietro Lampertico.;Maria Paola Anolli.;Dominique Roulot.;Heiner Wedemeyer.
来源: Gut. 2025年74卷5期853-862页
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated interferon alpha (PegIFN-α) has represented the only therapeutic option, with limited virological response rates and poor tolerability. In 2020, the European Medicines Agency approved bulevirtide (BLV) at 2 mg/day, an entry inhibitor of hepatitis B virus (HBV)/hepatitis delta virus (HDV), which proved to be safe and effective as a monotherapy for up to 144 weeks in clinical trials and real-life studies, including patients with cirrhosis. Long-term BLV monotherapy may reduce decompensating events in patients with cirrhosis. The combination of BLV 2 mg with PegIFN-α increased the HDV RNA undetectability rates on-therapy but not off-therapy, compared with PegIFN monotherapy. However, combination therapy, but not BLV monotherapy, may induce hepatitis B surface antigen (HBsAg) loss in some patients. The PegIFN lambda study has been discontinued due to liver toxicity issues, while lonafarnib boosted with ritonavir showed limited off-therapy efficacy in a phase 3 study. Nucleic acid polymer-based therapy is promising but large studies are still lacking. New controlled trial data come from molecules, such as monoclonal antibodies and/or small interfering RNA, that target HBsAg or HBV RNAs, which demonstrated not only profound HDV suppression, but also HBsAg decline.While waiting for new compounds to be approved as monotherapy or in combination, BLV monotherapy 2 mg/day remains the only approved therapy for CHD, at least in the European Union region.

178. Combining epigenetic modulation: the next step for HCC immunotherapy?

作者: Chi Ma.;Bertram Bengsch.
来源: Gut. 2025年74卷7期1033-1034页

179. Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events.

作者: Eleonora De Martin.;Claudia A M Fulgenzi.;Ciro Celsa.;Astrid Laurent-Bellue.;Aria Torkpour.;Pasquale Lombardi.;Antonio D'Alessio.;David J Pinato.
来源: Gut. 2025年74卷7期1165-1177页
Immune checkpoint inhibitors (ICI) have led to breakthrough improvements in the management of malignancy including hepatocellular (HCC) and biliary tract cancer, improving decades-old standards of care and increasing patient survival. In both liver tumour types, which commonly arise in the context of liver inflammation and underlying functional impairment, the lack of validated predictors of response underscores the need to balance predicted gains in survival with risk of treatment-related hepatoxicity and decompensation of underlying chronic liver disease.In addition, the liver is implicated in the toxicity associated with ICI therapy for non-liver cancers, which exhibits a high degree of variability in presentation and severity. An accurate assessment is mandatory for the diagnosis and management of ICI-induced liver injury.In this Recent Advances article, we provide an overview of the mechanisms of efficacy and toxicity of anticancer immunotherapy in liver tumours and liver toxicity in extrahepatic malignancies.We compare and contrast characteristics, management strategies and outcomes from immune-related liver injury in patients with chronic hepatitis/cirrhosis or with an underlying healthy liver and discuss the latest findings on how toxicity and decompensation may impact the outlook of patients with liver tumours and extrahepatic malignancies offering insights into the future directions of clinical research and practice in the field.

180. Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.

作者: Qi Jia.;Xiaoxiao Sun.;Haoyu Li.;Jianglong Guo.;Kongyan Niu.;Kui Ming Chan.;René Bernards.;Wenxin Qin.;Haojie Jin.
来源: Gut. 2025年74卷5期840-852页
Perturbation of mRNA splicing is commonly observed in human cancers and plays a role in various aspects of cancer hallmarks. Understanding the mechanisms and functions of alternative splicing (AS) not only enables us to explore the complex regulatory network involved in tumour initiation and progression but also reveals potential for RNA-based cancer treatment strategies. This review provides a comprehensive summary of the significance of AS in liver cancer, covering the regulatory mechanisms, cancer-related AS events, abnormal splicing regulators, as well as the interplay between AS and post-transcriptional and post-translational regulations. We present the current bioinformatic approaches and databases to detect and analyse AS in cancer, and discuss the implications and perspectives of AS in the treatment of liver cancer.
共有 18989 条符合本次的查询结果, 用时 4.1812617 秒